307 related articles for article (PubMed ID: 26854024)
21. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC; Tan SY; Tang T; Poon SL; Allen GE; Tan L; Chong SC; Ong WS; Tay K; Tao M; Quek R; Loong S; Yeoh KW; Yap SP; Lee KA; Lim LC; Tan D; Goh C; Cutcutache I; Yu W; Ng CC; Rajasegaran V; Heng HL; Gan A; Ong CK; Rozen S; Tan P; Teh BT; Lim ST
Cancer Discov; 2012 Jul; 2(7):591-7. PubMed ID: 22705984
[TBL] [Abstract][Full Text] [Related]
22. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
23. Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.
Veloza L; Cavalieri D; Missiaglia E; Ledoux-Pilon A; Bisig B; Pereira B; Bonnet C; Poullot E; Quintanilla-Martinez L; Dubois R; Llamas-Gutierrez F; Bossard C; De Wind R; Drieux F; Fontaine J; Parrens M; Sandrini J; Fataccioli V; Delfau-Larue MH; Daniel A; Lhomme F; Clément-Filliatre L; Lemonnier F; Cairoli A; Morel P; Glaisner S; Joly B; El Yamani A; Laribi K; Bachy E; Siebert R; Vallois D; Gaulard P; Tournilhac O; De Leval L
Haematologica; 2023 Jan; 108(1):181-195. PubMed ID: 35708139
[TBL] [Abstract][Full Text] [Related]
24. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
25. Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type.
Sim SH; Kim S; Kim TM; Jeon YK; Nam SJ; Ahn YO; Keam B; Park HH; Kim DW; Kim CW; Heo DS
Am J Pathol; 2017 May; 187(5):980-986. PubMed ID: 28284718
[TBL] [Abstract][Full Text] [Related]
26. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
Waldmann TA; Chen J
Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
[TBL] [Abstract][Full Text] [Related]
27. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
29. Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas.
Nicolae A; Xi L; Pham TH; Pham TA; Navarro W; Meeker HG; Pittaluga S; Jaffe ES; Raffeld M
Leukemia; 2016 Nov; 30(11):2245-2247. PubMed ID: 27389054
[No Abstract] [Full Text] [Related]
30. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
Vafadari R; Weimar W; Baan CC
Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
[TBL] [Abstract][Full Text] [Related]
31. The differential role of Jak/STAT signaling in retinal degeneration.
Lange C; Thiersch M; Samardzija M; Grimm C
Adv Exp Med Biol; 2010; 664():601-7. PubMed ID: 20238064
[TBL] [Abstract][Full Text] [Related]
32. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.
Viganò E; Gunawardana J; Mottok A; Van Tol T; Mak K; Chan FC; Chong L; Chavez E; Woolcock B; Takata K; Twa D; Shulha HP; Telenius A; Kutovaya O; Hung SS; Healy S; Ben-Neriah S; Leroy K; Gaulard P; Diepstra A; Kridel R; Savage KJ; Rimsza L; Gascoyne R; Steidl C
Blood; 2018 May; 131(18):2036-2046. PubMed ID: 29467182
[TBL] [Abstract][Full Text] [Related]
33. Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.
Moffitt AB; Ondrejka SL; McKinney M; Rempel RE; Goodlad JR; Teh CH; Leppa S; Mannisto S; Kovanen PE; Tse E; Au-Yeung RKH; Kwong YL; Srivastava G; Iqbal J; Yu J; Naresh K; Villa D; Gascoyne RD; Said J; Czader MB; Chadburn A; Richards KL; Rajagopalan D; Davis NS; Smith EC; Palus BC; Tzeng TJ; Healy JA; Lugar PL; Datta J; Love C; Levy S; Dunson DB; Zhuang Y; Hsi ED; Dave SS
J Exp Med; 2017 May; 214(5):1371-1386. PubMed ID: 28424246
[TBL] [Abstract][Full Text] [Related]
34. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract][Full Text] [Related]
35. Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
Lee S; Park HY; Kang SY; Kim SJ; Hwang J; Lee S; Kwak SH; Park KS; Yoo HY; Kim WS; Kim JI; Ko YH
Oncotarget; 2015 Jul; 6(19):17764-76. PubMed ID: 25980440
[TBL] [Abstract][Full Text] [Related]
36. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
38. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
[TBL] [Abstract][Full Text] [Related]
39. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
40. Jak/STAT and PI3K signaling pathways have both common and distinct roles in IL-7-mediated activities in human CD8+ T cells.
Crawley AM; Vranjkovic A; Faller E; McGuinty M; Busca A; Burke SC; Cousineau S; Kumar A; Macpherson PA; Angel JB
J Leukoc Biol; 2014 Jan; 95(1):117-27. PubMed ID: 24072878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
